• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
31MayMay 31, 2024

ARV-766, A PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Initial Results of a Phase 1/2 Study

03MayMay 3, 2024

ARV-766, a PROTAC Androgen Receptor Degrader, Combined With Abiraterone in Novel Hormonal Agent–Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 Study

27MarMarch 27, 2024

Drug-Drug Interaction Study of the PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Combination With the P-glycoprotein Substrate Fexofenadine in Healthy Male Volunteers

25JanJanuary 25, 2024

Real-World Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Tumors Harboring Androgen Receptor (AR) Ligand-Binding Domain (LBD) Mutations

20OctOctober 20, 2023

Phase 1/2 Study of Bavdegalutamide, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Radiographic Progression-Free Survival in Patients With Androgen Receptor Ligand-Binding Domain Mutation

10SepSeptember 10, 2023

In Vitro Evaluation of PROTAC® Androgen Receptor Degrader ARV-766 for Cytochrome P450- and Transporter-Mediated Drug-Drug Interaction

10SepSeptember 10, 2023

Drug-Drug Interaction Study of the PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Combination With the CYP3A4 Inhibitor Itraconazole in Healthy Volunteers

10SepSeptember 10, 2023

The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Healthy Volunteers

10SepSeptember 10, 2023

The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of ARV-766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Healthy Volunteers

14AprApril 14, 2023

Discovery of ARV-766, an Androgen Receptor Degrading PROTAC® for the Treatment of Men with Metastatic Castration Resistant Prostate Cancer

12Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE